HealthSTAR Strategic Engagements (HSE) is proud to announce the launch of another in its line of robust integration solutions with Veeva’s CRM and Events Managements product line, HSE’s third unique integration just in the Patient Engagements space.
SkinCeuticals, the #1 medical professional skincare brand in the US, announces the opening of SkinCeuticals SkinLab™ in partnership with Cosmetic Surgery Institute (CSI).
Cognate BioServices, Inc., the premier commercial-ready global CDMO in the Cell and Gene Therapy industry, and Nucleus Biologics, LLC, The Cell Performance Company™, announced today a partnership for custom and commercial medias and delivery systems for Cell and Gene Therapy clients.
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that two poster presentations will feature data on the new Bausch + Lomb INFUSE™ silicone hydrogel (SiHy) daily disposable contact lenses during the virtual Global Specialty Lens Symposium (GSLS).
Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the addition of state-of-the-art cellular analysis platforms at its Discovery Biology facility in Cambridge, Massachusetts, USA.
AXON Neuroscience SE ("Axon"), a clinical-stage biotech company pioneering research in neurodegenerative diseases with a unique peptide vaccine platform, announced positive pre-clinical results for ACvac1, its vaccine candidate against novel coronavirus SARS-CoV-2.
NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow ALS progression, announced today that PrimeC was safe and well tolerated in the interim analysis of study NST002, a Phase IIa study conducted by Principal Investigator Prof.
NCSolutions (NCS) and ciValue are collaborating to launch a new cloud-based retailer marketing service designed to support the personalized and relevant experience today's shoppers expect from retailers and brands.
People suffering from glaucoma got bad news and good news from a clinical study published in the journal Ophthalmology (1) this month.
Babson Diagnostics (Babson), a transformative diagnostic blood testing company, announced today that its SARS-CoV-2 IgG antibody test, Babson Diagnostics aC19G1, has received emergency use authorization (EUA) from the Food and Drug Administration (FDA).